Reports and investigative coverage show the Make America Healthy Again (MAHA) movement and HHS leadership under Robert F. Kennedy Jr. have advanced policy changes that reduce recommended childhood vaccines, restructure scientific leadership, and press alternative public‑health priorities. Journalistic accounts document agency staff turnover, grant cancellations, and shifts in vaccine scheduling that public‑health experts have criticized. A separate analysis detailed strategic recommendations from MAHA-aligned operatives urging legal and policy approaches to challenge liability protections, mandates, and the traditional vaccine schedule. Those recommendations aim to embed MAHA priorities into federal and state health policy and have prompted pushback from medical societies and immunization experts. The developments have immediate regulatory and commercial implications: vaccine developers face an uncertain U.S. policy backdrop even as global regulators continue standard review practices. Companies with pediatric and routine immunization portfolios are reassessing U.S. market access risk, stakeholder engagement plans, and communications strategies toward clinicians and payers.